Intrinsiqs

Is Prelude Therapeutics Incorporated overvalued?

Prelude Therapeutics Incorporated (PRLD) — key valuation metrics and fundamentals.

No verdict
Price
$5.55
Fair value
Current P/E
Normal P/E
Market cap
$316.0M
Dividend yield
0.0%
Return on equity
-75.4%
Sector
Healthcare

See the full interactive analysis →

Fair value compares PRLD's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 11 Aug 2026.